Top 5 Medical Stocks To Invest In 2019

Tilray has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 9.0 million shares in the range of $14 to $16 a piece, with an overallotment option for an additional 1.35 million shares. At the maximum price, the entire offering is valued up to $165.6 million. The company intends to list its stock on the Nasdaq under the symbol TLRY.

The underwriters for the offering are Cowen, Roth Capital Partners and Northland Capital Markets.

This company is pioneering the future of medical cannabis research, cultivation, processing and distribution globally, and it intends to become a leader in the adult-use cannabis market in Canada once legalized later this year.

Tilray has supplied high-quality cannabis products to tens of thousands of patients in 10 countries spanning five continents through its subsidiaries in Australia, Canada and Germany and through agreements with established pharmaceutical distributors, and it produces medical cannabis in Canada and Europe.

Top 5 Medical Stocks To Invest In 2019: Sociedad Quimica y Minera S.A.(SQM)

Advisors’ Opinion:

  • [By Beth McKenna]

    China’s Tianqi Lithium Corp. has struck a deal to buy a 24% stake in Sociedad Quimica y Minera de Chile (NYSE:SQM), or SQM, for $4.07 billion, the companies involved said on Thursday.

  • [By Jim Robertson]

    Morgan Stanley analysts had issued a report predicting that the cost of the lithium could fall 45% by 2021 and they also downgraded key lithium producers Albemarle Corporation (NYSE: ALB) and Chiles Sociedad Quimica y Minera de Chile (NYSE: SQM) to “underweight” from “equal weight.

  • [By Jim Robertson]

    It should be noted that FMC Corp together with Albemarle Corporation (NYSE: ALB) and Chiles Sociedad Quimica y Minera de Chile (NYSE: SQM) forma so-called lithium oligopoly that tends to dominate global production. A recent Bloomberg article noted that Albemarle Chief Executive Officer Luke Kissam had said in March that hes also eager to see how the value settles for the FMC lithium spinoff. Iftheprice-to-earnings ratio is high enough,then they would look to create a pure-play lithium business byselling off non-lithium units. If FMC Corp and Albemarle Corporation do end upcompletingthese spin-offs, thatwill be good news for the valuations of all lithium players as the market will put clear valuation numbers onthese larger pure play lithium businesses which will help provide valuation benchmarks for other small cap lithium players.

  • [By Beth McKenna]

    Now that the three big lithium companies that trade on a major U.S. stock exchange –Albemarle (NYSE:ALB), Sociedad Quimica y Minera de Chile(NYSE:SQM), or SQM,and FMC Corp. (NYSE:FMC). — have reported their first-quarter 2018 results, we’re going to compare how their respective lithium businesses performed.

Top 5 Medical Stocks To Invest In 2019: Kona Grill Inc.(KONA)

Advisors’ Opinion:

  • [By Max Byerly]

    Kona Grill (NASDAQ: KONA) and Yum! Brands (NYSE:YUM) are both retail/wholesale companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

  • [By Logan Wallace]

    News stories about Kona Grill (NASDAQ:KONA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Kona Grill earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave press coverage about the restaurant operator an impact score of 47.6558176409177 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

  • [By Lisa Levin] Gainers
    Precipio, Inc. (NASDAQ: PRPO) jumped 43.3 percent to $0.5447 after the micro-cap specialty diagnostics company reported preliminary first-quarter results. The company said its first quarter revenue rose 286 percent from the same quarter a year ago to $712,000.
    Galectin Therapeutics, Inc. (NASDAQ: GALT) gained 34.5 percent to $4.52 after the company announced it would proceed with Phase 3 development of GR-MD-02 for NASH Cirrhosis following the FDA meeting.
    Boxlight Corporation (NASDAQ: BOXL) shares rose 21.9 percent to $8.1063.
    Evolus, Inc. (NASDAQ: EOLS) shares surged 16 percent to $15.65.
    Myomo, Inc. (NYSE: MYO) shares jumped 15.5 percent to $3.6263 after the company disclosed that its application for Medicare codes received favorable preliminary decision.
    Tandem Diabetes Care, Inc. (NASDAQ: TNDM) rose 13.7 percent to $10.12.
    ProPhase Labs, Inc. (NASDAQ: PRPH) gained 13.7 percent to $4.6743.
    Acacia Communications, Inc. (NASDAQ: ACIA) shares gained 12.2 percent to $35.34 as optical sector is seeing strength following President Trump's announcement that he would work with China related to ZTE Corp.
    Tailored Brands, Inc. (NYSE: TLRD) shares rose 11.3 percent to $35.17. Jefferies upgraded Tailored Brands from Hold to Buy.
    Kona Grill, Inc. (NASDAQ: KONA) jumped 10.6 percent to $2.875.
    Federated National Holding Company (NASDAQ: FNHC) shares rose 10.6 percent to $20.29. Raymond James upgraded Federated National Holding from Outperform to Strong Buy.
    Renewable Energy Group, Inc. (NASDAQ: REGI) climbed 10.2 percent to $15.15. Renewable Energy will replace Synchronoss Technologies Inc. (NASDAQ: SNCR) in the S&P SmallCap 600 on Tuesday, May 15.
    Stein Mart, Inc. (NASDAQ: SMRT) shares climbed 10.1 percent to $3.16. Stein Mart is expected to release Q1 earnings on May 23.
    NXP Semiconductors N.V. (NASDAQ: NXPI) rose 9.7 percent to $108.60 after Bloomberg reported that the China’s Commerce Ministry has restar

Top 5 Medical Stocks To Invest In 2019: Nuveen North Carolina Premium Income Municipal Fund(NNC)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Wells Fargo & Company MN increased its holdings in Nuveen North Carol Premium Incom Mun Fd (NYSE:NNC) by 29.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 289,655 shares of the financial services provider’s stock after purchasing an additional 66,507 shares during the quarter. Wells Fargo & Company MN’s holdings in Nuveen North Carol Premium Incom Mun Fd were worth $3,554,000 at the end of the most recent reporting period.

Top 5 Medical Stocks To Invest In 2019: Gencor Industries Inc.(GENC)

Advisors’ Opinion:

  • [By Max Byerly]

    Gencor Industries, Inc. (DE) (NASDAQ:GENC) major shareholder Sherry Houtkin sold 1,892 shares of the firm’s stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $16.17, for a total transaction of $30,593.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Top 5 Medical Stocks To Invest In 2019: Gartner, Inc.(IT)

Advisors’ Opinion:

  • [By Danny Vena]

    It isn’t just investors and analysts bestowing praise on Salesforce, but those that provide the rankings for the industry as well. In fact, Salesforce was recently named a leader in Gartner’s (NYSE:IT) Magic Quadrant for the CRM Customer Engagement Center for the 10th consecutive year running.

  • [By Steve Symington]

    Gartner Inc. (NYSE:IT) announced better-than-expected first-quarter 2018 results on Tuesday, detailing double-digit percentage growth led by strong demand for its market-leading research-and-advisory services. The company also modestly reduced its full-year guidance, but only to reflect the impact of recent divestitures.

  • [By Joseph Griffin]

    Gartner (NYSE:IT) was downgraded by analysts at ValuEngine from a buy rating to a hold rating.

    Intra-Cellular Therapies (NASDAQ:ITCI) was downgraded by analysts at ValuEngine from a buy rating to a hold rating.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Gartner (IT)

    For more information about research offerings from Zacks Investment Research, visit

Leave a Reply

Your email address will not be published. Required fields are marked *